These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Ligand based virtual screening and biological evaluation of inhibitors of chorismate mutase (Rv1885c) from Mycobacterium tuberculosis H37Rv. Agrawal H; Kumar A; Bal NC; Siddiqi MI; Arora A Bioorg Med Chem Lett; 2007 Jun; 17(11):3053-8. PubMed ID: 17418569 [TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis. Upadhayaya RS; Kulkarni GM; Vasireddy NR; Vandavasi JK; Dixit SS; Sharma V; Chattopadhyaya J Bioorg Med Chem; 2009 Jul; 17(13):4681-92. PubMed ID: 19457676 [TBL] [Abstract][Full Text] [Related]
25. 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. Karabanovich G; Roh J; Smutný T; Němeček J; Vicherek P; Stolaříková J; Vejsová M; Dufková I; Vávrová K; Pávek P; Klimešová V; Hrabálek A Eur J Med Chem; 2014 Jul; 82():324-40. PubMed ID: 24927053 [TBL] [Abstract][Full Text] [Related]
26. Discovery of Schaeffer's acid analogues as lead structures of mycobacterium tuberculosis type II dehydroquinase using a rational drug design approach. Schmidt MF; Korb O; Howard NI; Dias MV; Blundell TL; Abell C ChemMedChem; 2013 Jan; 8(1):54-8. PubMed ID: 23169689 [TBL] [Abstract][Full Text] [Related]
27. Antifungal and antimycobacterial activity of new imidazole and triazole derivatives. A combined experimental and computational approach. Banfi E; Scialino G; Zampieri D; Mamolo MG; Vio L; Ferrone M; Fermeglia M; Paneni MS; Pricl S J Antimicrob Chemother; 2006 Jul; 58(1):76-84. PubMed ID: 16709593 [TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological evaluation of new cinnamic derivatives as antituberculosis agents. De P; Koumba Yoya G; Constant P; Bedos-Belval F; Duran H; Saffon N; Daffé M; Baltas M J Med Chem; 2011 Mar; 54(5):1449-61. PubMed ID: 21309577 [TBL] [Abstract][Full Text] [Related]
29. New quinolin-4-yl-1,2,3-triazoles carrying amides, sulphonamides and amidopiperazines as potential antitubercular agents. Thomas KD; Adhikari AV; Chowdhury IH; Sumesh E; Pal NK Eur J Med Chem; 2011 Jun; 46(6):2503-12. PubMed ID: 21489660 [TBL] [Abstract][Full Text] [Related]
30. Synthesis of quinoline coupled [1,2,3]-triazoles as a promising class of anti-tuberculosis agents. Karthik Kumar K; Prabu Seenivasan S; Kumar V; Mohan Das T Carbohydr Res; 2011 Oct; 346(14):2084-90. PubMed ID: 21767828 [TBL] [Abstract][Full Text] [Related]
31. Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: part 2. Synthesis of rigid pyrazolones. Castagnolo D; Manetti F; Radi M; Bechi B; Pagano M; De Logu A; Meleddu R; Saddi M; Botta M Bioorg Med Chem; 2009 Aug; 17(15):5716-21. PubMed ID: 19581099 [TBL] [Abstract][Full Text] [Related]
32. Molecular model of shikimate kinase from Mycobacterium tuberculosis. Filgueira de Azevedo W; Canduri F; Simões de Oliveira J; Basso LA; Palma MS; Pereira JH; Santos DS Biochem Biophys Res Commun; 2002 Jul; 295(1):142-8. PubMed ID: 12083781 [TBL] [Abstract][Full Text] [Related]
33. Structure-based design of a potent and selective small peptide inhibitor of Mycobacterium tuberculosis 6-hydroxymethyl-7, 8-dihydropteroate synthase: a computer modelling approach. Rao GS; Kumar M Chem Biol Drug Des; 2008 Jun; 71(6):540-5. PubMed ID: 18482337 [TBL] [Abstract][Full Text] [Related]
34. Comparative protein modeling of methionine S-adenosyltransferase (MAT) enzyme from Mycobacterium tuberculosis: a potential target for antituberculosis drug discovery. Khedkar SA; Malde AK; Coutinho EC J Mol Graph Model; 2005 Jan; 23(4):355-66. PubMed ID: 15670956 [TBL] [Abstract][Full Text] [Related]
35. Development of an ESI-LC-MS-based assay for kinetic evaluation of Mycobacterium tuberculosis shikimate kinase activity and inhibition. Simithy J; Gill G; Wang Y; Goodwin DC; Calderón AI Anal Chem; 2015 Feb; 87(4):2129-36. PubMed ID: 25629762 [TBL] [Abstract][Full Text] [Related]
36. Synthesis, molecular docking, and biological evaluation of novel 1,2,4-triazole-isatin derivatives as potential Mycobacterium tuberculosis shikimate kinase inhibitors. Dadlani VG; Chhabhaiya H; Somani RR; Tripathi PK Chem Biol Drug Des; 2022 Aug; 100(2):230-244. PubMed ID: 35434882 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of M. tuberculosis β-ketoacyl CoA reductase FabG4 (Rv0242c) by triazole linked polyphenol-aminobenzene hybrids: comparison with the corresponding gallate counterparts. Banerjee DR; Senapati K; Biswas R; Das AK; Basak A Bioorg Med Chem Lett; 2015 Mar; 25(6):1343-7. PubMed ID: 25666821 [TBL] [Abstract][Full Text] [Related]
38. A new family of inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase. Gasse C; Huteau V; Douguet D; Munier-Lehmann H; Pochet S Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1057-61. PubMed ID: 18058536 [No Abstract] [Full Text] [Related]
39. Thiosemicarbazones, semicarbazones, dithiocarbazates and hydrazide/hydrazones: anti-Mycobacterium tuberculosis activity and cytotoxicity. Pavan FR; da S Maia PI; Leite SR; Deflon VM; Batista AA; Sato DN; Franzblau SG; Leite CQ Eur J Med Chem; 2010 May; 45(5):1898-905. PubMed ID: 20163897 [TBL] [Abstract][Full Text] [Related]
40. When inhibitors do not inhibit: critical evaluation of rational drug design targeting chorismate mutase from Mycobacterium tuberculosis. Munack S; Leroux V; Roderer K; Ökvist M; van Eerde A; Gundersen LL; Krengel U; Kast P Chem Biodivers; 2012 Nov; 9(11):2507-27. PubMed ID: 23161632 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]